超声引导下无水乙醇、聚桂醇治疗巨大单纯性肝囊肿的疗效观察

肝脏 ›› 2026, Vol. 31 ›› Issue (4): 536-538.

超声引导下无水乙醇、聚桂醇治疗巨大单纯性肝囊肿的疗效观察

吕慧, 刘帅, 刘计龙, 吕平平

234200 宿州安徽省灵璧县人民医院超声科(吕慧,吕平平),普外科(刘帅,刘计龙)

收稿日期:2025-10-10 出版日期:2026-04-30 发布日期:2026-06-04
通讯作者: 吕平平, Email: 13956884321.163.com

Efficacy of ultrasound-guided anhydrous ethanol and lauromacrogol sclerotherapy in the treatment of giant simple hepatic cysts

LV Hui¹, LIU Shuai², LIU Ji-long², LV Ping-ping¹

1. Department of Ultrasound, Lingbi People′s Hospital, Anhui Province, Suzhou 234200, China;
2. General Surgery, Lingbi People′s Hospital, Suzhou 234200, China

Received:2025-10-10 Online:2026-04-30 Published:2026-06-04
Contact: LV Ping-ping, Email: 13956884321.163.com

摘要/Abstract

摘要： 目的比较巨大单纯性肝囊肿(GSHC)患者采用超声引导下经皮穿刺引流结合无水乙醇与聚桂醇硬化治疗的疗效。方法收集2022年1月至2024年12月安徽省灵璧县人民医院收治的GSHC患者94例,根据治疗方法的不同分为无水乙醇组(n=52)、聚桂醇组(n=42),比较两组在囊肿体积退缩率、机体应激反应指标、不良反应等方面的差异。结果治疗后1个月、3个月、6个月,聚桂醇组囊肿体积退缩率分别为(67.0±8.6)%、(82.6±7.8)%、(93.8±7.0)%,均显著高于无水乙醇组[(55.4±7.1)%、(74.5±6.3)%、(84.3±6.5)%,P<0.05]。治疗1周后,无水乙醇组NE、glu、乳酸分别升高至(405.8±54.5)pg/mL、(6.2±0.8)mmol/L、(2.1±0.5)mmol/L,升幅均大于聚桂醇组[(366.5±46.2)pg/mL、(5.5±0.6)mmol/L、(1.8±0.4)mmol/L,P<0.05]。无水乙醇组不良反应发生率为30.8%(15/52),显著高于聚桂醇组[9.5%(4/42),P<0.05]。结论超声引导下聚桂醇硬化治疗对GSHC具有更优的体积缩小效果、较轻的全身与局部炎性应激反应及更好的安全性,值得在临床中优先考虑,尤其在高风险患者中具有推广价值。

关键词: 单纯性肝囊肿, 无水乙醇, 聚桂醇, 应激指标, 炎症因子

Abstract: Objective To compare the therapeutic efficacy of ultrasound-guided percutaneous aspiration combined with anhydrous ethanol or lauromacrogol sclerotherapy in patients with giant simple hepatic cysts (GSHC). Methods A total of 94 patients with GSHC treated between January 2022 and December 2024 in Lingbi People′s Hospital were enrolled. According to the sclerosing agent used, patients were assigned to the absolute ethanol group (n=52) or the lauromacrogol group (n=42). The cyst volume reduction rate, systemic stress response indicators, and adverse events were compared between the two groups. Results At 1, 3, and 6 months after treatment, the cyst volume reduction rates in the lauromacrogol group were (67.0±8.6)%, (82.6±7.8)%, and (93.8±7.0)%, respectively, all significantly higher than those in the absolute ethanol group [(55.4±7.1) %, (74.5±6.3) %, and (84.3±6.5) %, P<0.05]. One week after treatment, NE, glu, and lactate levels in the absolute ethanol group increased to (405.8±54.5) pg/mL, (6.2±0.8) mmol/L, and (2.1±0.5) mmol/L, respectively, with greater elevations than those observed in the lauromacrogol group [(366.5±46.2) pg/mL, (5.5±0.6) mmol/L, and (1.8±0.4) mmol/L, P<0.05]. The incidence of adverse reactions in the absolute ethanol group was 30.8% (15/52), significantly higher than that in the lauromacrogol group [9.5% (4/42), P<0.05]. Conclusion Ultrasound-guided lauromacrogol sclerotherapy for GSHC provides superior cyst volume reduction, milder systemic and local inflammatory stress responses, and better safety compared with anhydrous ethanol, making it a preferred option in clinical practice, particularly for high-risk patients.

Key words: Simple hepatic cyst, Absolute ethanol, Lauromacrogol, Stress markers, Inflammatory cytokines

吕慧, 刘帅, 刘计龙, 吕平平. 超声引导下无水乙醇、聚桂醇治疗巨大单纯性肝囊肿的疗效观察[J]. 肝脏, 2026, 31(4): 536-538.

LV Hui, LIU Shuai, LIU Ji-long, LV Ping-ping. Efficacy of ultrasound-guided anhydrous ethanol and lauromacrogol sclerotherapy in the treatment of giant simple hepatic cysts[J]. Chinese Hepatolgy, 2026, 31(4): 536-538.

/ 推荐

参考文献

[1] Kumar A, Zendel A, Batres M, et al. Radiologic reporting of simple hepatic cyst versus biliary cystadenoma may lead to unnecessary surgery[J]. Am Surg, 2023, 89(5):1392-1395.
[2] Chen C, Zhang R, Wan R. Novel technique for treating simple hepatic cysts: endoscopic transgastric hepatic cyst deroofing[J]. Endoscopy, 2022, 54(S 2):E1045-E1046.
[3] 张琼, 陈士颖, 夏维. 超声引导下无水乙醇与聚桂醇硬化治疗单纯性肝囊肿患者效果比较研究[J]. 实用肝脏病杂志, 2023, 26(3):428-431.
[4] Jang S Y, Park S Y, Tak W Y, et al. Long-term follow-up of large symptomatic hepatic cysts treated by percutaneous ethanol sclerotherapy[J]. Acta Radiol, 2016, 57(10):1205-1209.
[5] Mamidi I S, Lee E, Benito D A, et al. Ultrasound-guided ethanol sclerotherapy for non-surgical treatment of Warthin′s tumor[J]. Am J Otolaryngol, 2021, 42(1):102813.
[6] Zhang H, Zhang C, Liu Y, et al. Comparison of CT-guided intracystic lidocaine pre-injection versus conventional US-guided single-session ethanol sclerotherapy for simple hepatic cysts[J]. Sci Rep, 2025, 15(1):13303.
[7] Wang S, Yin M, Xia Z. Efficacy and preliminary dose studies of ultrasound-guided sclerotherapy with lauromacrogol for the treatment of implanted hepatic tumors in rabbits[J]. J Gastrointest Oncol, 2023, 14(1):265-277.
[8] Yang S, Huang D. Application of ultrasound-guided microwave ablation combined with polidocanol injection in benign cystic-solid thyroid nodules and recurrence analysis[J]. Discov Oncol, 2025, 16(1):736.
[9] Kahraman G, Haberal K M, Dilek O N. Imaging features and management of focal liver lesions[J]. World J Radiol, 2024, 16(6):139-167.
[10] Li K, Jiang Y, Wei Z, et al. Lauromacrogol foam injection under ultrasonic guidance for pediatric lip venous malformations[J]. Pediatr Surg Int, 2023, 39(1):93.
[11] Wang Q, Wu Y X, Zhang M X, et al. Efficacy of bleomycin-lauromacrogol foam in pediatric macrocystic lymphatic malformations with and without intracapsular hemorrhage[J]. J Pediatr Surg, 2024, 59(6):1128-1134.
[12] Duan Y, Pan X, Luo J, et al. Association of inflammatory cytokines with non-alcoholic fatty liver disease[J]. Front Immunol, 2022, 13:880298.
[13] Pratim Das P, Medhi S. Role of inflammasomes and cytokines in immune dysfunction of liver cirrhosis[J]. Cytokine, 2023, 170:156347.
[14] Qin S, Liu Y, Ning H, et al. EUS-guided lauromacrogol ablation of insulinomas: a novel treatment[J]. Scand J Gastroenterol, 2018, 53(5):616-620.
[15] Xu S, Rao M, Pu Y, et al. The efficacy of laparoscopic lauromacrogol sclerotherapy in the treatment of simple hepatic cysts located in posterior segments: a refined surgical approach[J]. Ann Palliat Med, 2020, 9(5):3462-3471.